Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Wolfgang Fleischhacker, Silvana Galderisi, I. Laszlovszky, et al.
European Psychiatry (2019) Vol. 58, pp. 1-9
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 338
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Christoph U. Correll, Robert E. Davis, Michal Weingart, et al.
JAMA Psychiatry (2020) Vol. 77, Iss. 4, pp. 349-349
Open Access | Times Cited: 256
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Antonio Vita, Wolfgang Gäebel, Armida Mucci, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 88
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 60
The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
Roger S. McIntyre, David G. Daniel, Eduard Vieta, et al.
CNS Spectrums (2022) Vol. 28, Iss. 3, pp. 319-330
Open Access | Times Cited: 45
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
Béla Kiss, I. Laszlovszky, Balázs Krámos, et al.
Biomolecules (2021) Vol. 11, Iss. 1, pp. 104-104
Open Access | Times Cited: 51
Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel
Andrea Fagiolini, J.Á. Cuesta Alcalá, Thomas Aubel, et al.
Annals of General Psychiatry (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 43
A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders
Sélim Benjamin Guessoum, Yann Le Strat, Caroline Dubertret, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 99, pp. 109862-109862
Open Access | Times Cited: 42
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
Qiongqiong Wu, Xiaoyi Wang, Ying Wang, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 11, pp. 1609-1624
Open Access | Times Cited: 41
New Antipsychotic Medications in the Last Decade
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, et al.
Current Psychiatry Reports (2021) Vol. 23, Iss. 12
Closed Access | Times Cited: 37
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, et al.
Clinical Psychopharmacology and Neuroscience (2021) Vol. 19, Iss. 1, pp. 174-178
Open Access | Times Cited: 33
Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia
Giulia Maria Giordano, Edoardo Caporusso, Pasquale Pezzella, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 7, pp. 541-555
Open Access | Times Cited: 28
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review
Ebenezer Oloyede, Ivana Clark, Shubhra Mace, et al.
Therapeutic Advances in Psychopharmacology (2022) Vol. 12, pp. 204512532110666-204512532110666
Open Access | Times Cited: 24
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives
Irene Calzavara‐Pinton, Gabriele Nibbio, Sergio Barlati, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 791-791
Open Access | Times Cited: 4
The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
Elmārs Rancāns, Z.B. Dombi, Péter Mátrai, et al.
International Clinical Psychopharmacology (2021) Vol. 36, Iss. 3, pp. 154-161
Open Access | Times Cited: 25
Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature
Giulia Maria Giordano, Francesco Brando, Pasquale Pezzella, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
Mária Judit Molnár, Viktor Molnár, Mariann Fedor, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 17
The awareness, characterization, and burden of Cognitive Impairment Associated with Schizophrenia (CIAS) in clinical practice: Results from a nationwide survey in Italy
Antonio Vita, Sergio Barlati, Roberto Cavallaro, et al.
Schizophrenia Research Cognition (2025) Vol. 40, pp. 100352-100352
Closed Access
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Prakash S. Masand, Mousam Parikh, Jamie T. Ta, et al.
Journal of Medical Economics (2025), pp. 1-29
Open Access
Construction and application of magnetic surface molecularly imprinted solid-phase extraction for the detection of 5-hydroxytryptamine in peripheral blood
Guihua Zhu, Xinyu Li, Qianjie Ma, et al.
Microchimica Acta (2025) Vol. 192, Iss. 4
Closed Access
DYNAMICS OF CLINICAL AND PSYCHOPATHOLOGICAL STRUCTURE AND SEVERITY OF NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
Yu. A. Kushnir, K. V. Shevchenko-Bitensky
Bulletin of Problems Biology and Medicine (2025) Vol. 1, Iss. 1, pp. 227-227
Open Access
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder
Roger S. McIntyre, Vladimir Maletic, Prakash S. Masand, et al.
Journal of Affective Disorders (2025)
Open Access
Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
Ginetta Collo, Armida Mucci, Giulia Maria Giordano, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 24
Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
Octavia Căpățînă, I. Micluția, Mihaela Fadgyas Stănculete
Experimental and Therapeutic Medicine (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top